Work for Minerva Neurosciences, Inc?

Claim Your Profile

Minerva Neurosciences, Inc Logo Image

Minerva Neurosciences, Inc

About Minerva Neurosciences, Inc

11-50 Employees
Based in Waltham, Massachusetts

Minerva’s portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia; a potential royalty stream from seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV”.

Ticker:
NERV
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol